Evidence map›Paper›PMID 29073907›Full record

ArticleParticle and fibre toxicology2017

Multiparametric analysis of anti-proliferative and apoptotic effects of gold nanoprisms on mouse and human primary and transformed cells, biodistribution and toxicity in vivo.

Marta Pérez-Hernández, María Moros, Grazyna Stepien, Pablo Del Pino, Sebastián Menao, Marcelo de Las Heras, Maykel Arias, Scott G Mitchell, Beatriz Pelaz, Eva M Gálvez and 2 more

Abstract read
In one paragraph

Article in Particle and fibre toxicology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marta Pérez-HernándezDepartamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, 50009, Zaragoza, Spain. martaperezh@gmail.com.ORCID 0000-0003-1331-5493
María MorosInstituto Universitario de Nanociencia de Aragón (INA), Universidad de Zaragoza, 50018, Zaragoza, Spain.
Grazyna StepienFundación Instituto Universitario de Nanociencia de Aragón (FINA), Universidad de Zaragoza, 50018, Zaragoza, Spain.
Pablo Del PinoInstituto Universitario de Nanociencia de Aragón (INA), Universidad de Zaragoza, 50018, Zaragoza, Spain.
Sebastián MenaoDepartamento de Bioquímica clínica. H.C.U. Lozano Blesa, 50009, Zaragoza, Spain.
Marcelo de Las HerasDepartamento de Patología Animal, Facultad de Veterinaria, Universidad de Zaragoza, 50009, Zaragoza, Spain.
Maykel AriasInstituto de Investigación Sanitaria de Aragón (IIS Aragón), Centro de Investigación Biomédica de Aragón (CIBA), Universidad de Zaragoza, 50009, Zaragoza, Spain.
Scott G MitchellInstituto de Ciencia de Materiales de Aragón, CSIC-Universidad de Zaragoza, Zaragoza, Spain.
Beatriz PelazInstituto Universitario de Nanociencia de Aragón (INA), Universidad de Zaragoza, 50018, Zaragoza, Spain.
Eva M GálvezInstituto de Carboquímica ICB-CSIC, 50018, Zaragoza, Spain.
Jesús M de la FuenteCIBER in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Zaragoza, Spain.
Julián PardoInstituto de Investigación Sanitaria de Aragón (IIS Aragón), Centro de Investigación Biomédica de Aragón (CIBA), Universidad de Zaragoza, 50009, Zaragoza, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe special physicochemical properties of gold nanoprisms make them very useful for biomedical applications including biosensing and cancer therapy. However, it is not clear how gold nanoprisms may affect cellular physiology including viability and other critical functions. We report a multiparametric investigation on the impact of gold-nanoprisms on mice and human, transformed and primary cells as well as tissue distribution and toxicity in vivo after parental injection.

methodsCellular uptake of the gold-nanoprisms (NPRs) and the most crucial parameters of cell fitness such as generation of reactive oxygen species (ROS), mitochondria membrane potential, cell morphology and apoptosis were systematically assayed in cells. Organ distribution and toxicity including inflammatory response were analysed in vivo in mice at 3 days or 4 months after parental administration.

resultsInternalized gold-nanoprisms have a significant impact in cell morphology, mitochondrial function and ROS production, which however do not affect the potential of cells to proliferate and form colonies. In vivo NPRs were only detected in spleen and liver at 3 days and 4 months after administration, which correlated with some changes in tissue architecture. However, the main serum biochemical markers of organ damage and inflammation (TNFα and IFNγ) remained unaltered even after 4 months. In addition, animals did not show any macroscopic sign of toxicity and remained healthy during all the study period.

conclusionOur data indicate that these gold-nanoprisms are neither cytotoxic nor cytostatic in transformed and primary cells, and suggest that extensive parameters should be analysed in different cell types to draw useful conclusions on nanomaterials safety. Moreover, although there is a tendency for the NPRs to accumulate in liver and spleen, there is no observable negative impact on animal health.

Indexed as

A549 CellsAnimalsApoptosisCell Line, TransformedCell ProliferationCell ShapeFemaleGoldHeLa CellsHumansInflammation MediatorsInjections, IntravenousInterferon-gammaMaleMembrane Potential, MitochondrialMetal NanoparticlesGoldIFNG protein, mouseInflammation MediatorsInterferon-gammaReactive Oxygen SpeciesTumor Necrosis Factor-alphaBiodistributionGold nanoprismsIn vivoMitochondrial membrane-potentialNanotoxicologyROS generation

Identifiers

PMID29073907
PMCPMC5658988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.